Reactivation of the Silenced Thyroid Hormone Receptor β Gene Expression Delays Thyroid Tumor Progression
Open Access
- 1 January 2013
- journal article
- research article
- Published by The Endocrine Society in Endocrinology
- Vol. 154 (1) , 25-35
Abstract
That a knock-in mouse harboring a dominant-negative thyroid hormone receptor (TR)-β (Thrb) mutation develops metastatic thyroid cancer strongly suggests the involvement of TRβ in carcinogenesis. Epigenetic silencing of the THRB gene is common in human cancers. The aim of the present study was to determine how DNA methylation affected the expression of the THRB gene in differentiated thyroid cancer (DTC) and how reexpression of the THRB gene attenuated the cancer phenotypes. We used methylation-specific PCR to examine the expression and promoter methylation of the THRB gene in DTC tissues. Thyroid cancer cells with hypermethylated THRB were treated with the demethylating agents 5′-aza-2′-deoxycytidine (5′-aza-CdR) and zebularine to evaluate their impact on the cancer cell phenotypes. THRB mRNA expression in DTC was 90% lower than in normal controls, and this decrease was associated with a higher tumor/lymph node staging. The promoter methylation level of the THRB gene had a significant negative correlation with the expression level of the THRB gene. Treatment of FTC-236 cells with 5′-aza-CdR or zebularine induced reexpression of the THRB gene and inhibited cell proliferation and migration. FTC-236 cells stably expressing TRβ exhibited lower cell proliferation and migration through inhibition of β-catenin signaling pathways compared with FTC-236 without TRβ. 5′-Aza-CdR also led to suppression of tumor growth in an in vivo xenograft model using FTC-236 cells consistent with the cell-based studies. These finding indicate that TRβ is a tumor suppressor and could be tested as a potential therapeutic target.Keywords
This publication has 36 references indexed in Scilit:
- Aberrant methylation of the THRB gene in tissue and plasma of breast cancer patientsCancer Genetics and Cytogenetics, 2010
- Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2′-deoxycytidine and retinoic acidMolecular and Cellular Endocrinology, 2009
- International patterns and trends in thyroid cancer incidence, 1973–2002Cancer Causes & Control, 2008
- Retinoic acid receptor β2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2′-deoxycytidine treatmentJournal of Endocrinological Investigation, 2008
- Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applicationsJournal of Cellular Physiology, 2007
- The many ways of Wnt in cancerCurrent Opinion in Genetics & Development, 2007
- Thyroid hormone receptor β1 in normal colon and colorectal cancer–association with differentiation, polypoid growth type and K‐ras mutationsInternational Journal of Cancer, 2005
- Preferential response of cancer cells to zebularineCancer Cell, 2004
- Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cellsMolecular Carcinogenesis, 1999
- Interaction of Thyroid-Hormone Nuclear Receptor with Antibody: Characterization of the Thyroid Hormone Binding SiteBiochemical and Biophysical Research Communications, 1995